Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, ...

Moonshot AI's Kimi K3 could encourage a surge in enterprise workloads and provide a long-term tailwind to chip demand Moonshot AI paused new sign-ups for Kimi K3 over the weekend in response to ...

Chinese start-up pauses Kimi K3 subscriptions due to surging demand and compute shortages, highlighting the country's AI chip challenges Chinese start-up Moonshot AI has suspended new subscriptions ...